Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 8/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolfenamic Acid SCHEMBL8060884 | 1.00 | MT-CO2 (1.00) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL25190 | 1.00 | MT-CO2 (1.00) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL29484181 | 1.00 | MT-CO2 (1.00) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL27540385 | 0.98 | MT-CO2 (0.97) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL10619715 | 0.94 | MT-CO2 (0.89) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL28095333 | 0.93 | MT-CO2 (0.86) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL28229025 | 0.90 | MT-CO2 (0.82) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL14976730 | 0.90 | MT-CO2 (0.82) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| SCHEMBL11564152 | 0.88 | MT-CO2 (0.78) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| SCHEMBL12608896 | 0.87 | MT-CO2 (0.77) | MT-CO2PTGS2MEN1AKR1C3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023001045-A9 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-10-26 | — | — | WO | claimed |
| US-20260083751-A1 | ALLOSTERIC MODULATORS OF ANDROGEN RECEPTOR COACTIVATOR RECRUITMENT FOR CRPC THERAPY | UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-03-26 | — | — | US | disclosed |
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | PARKER DANE K (US) | 2026-02-10 | — | — | US | disclosed |
| US-12508227-B2 | Dry powder compositions with magnesium stearate | Aspeya US Inc. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250295871-A1 | AN INHALER COMPRISING A RETENTION ELEMENT | Vectura Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | COVAL BIOPHARMA (SHANGHAI)CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| US-12343425-B2 | Dry powder formulations for inhalation | Aspeya US Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-12329899-B2 | Dry powder inhaler and methods of use | Aspeya US Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4561656-A1 | AN INHALER COMPRISING A RETENTION ELEMENT | Aspeya US Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20220262507-A1 | PHARMACEUTICAL AND BIOLOGICAL AGENT DELIVERY SYSTEM HAVING BIOMETRIC DATA ACQUISITION AND MONITORING CAPABILITIES | SUMNER BLUFFS LLC (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114891070-A | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220246263-A1 | NEBULIZING DEVICES AND SYSTEMS HAVING BIOMETRIC DATA ACQUISITION AND MONITORING CAPABILITIES | SUMNER BLUFFS LLC (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3107548-B1 | DRY POWDER FORMULATIONS FOR INHALATION | OTITOPIC INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220168516-A1 | PRODUCT DELIVERY DEVICES AND METHODS | BREATHE RESTORE, INC. | 2022-06-02 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022089614-A1 | APPLICATION OF THYMIDINE DERIVATIVE IN PREPARATION OF DRUGS | 上海岸阔医药科技有限公司 | 2022-05-05 | — | — | WO | disclosed |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220040206-A1 | DRY POWDER FORMULATIONS FOR INHALATION | OTITOPIC INC (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241921-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | MT-CO2 1289/4885PTGS2 37/4885MEN1 4000/4885 |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | MT-CO2 3732/4885PTGS2 1368/4885MEN1 4875/4885 |
| US-12508227-B2 | Dry powder compositions with magnesium stearate | ACMSD, SARAF, TMCO1 | MT-CO2 318/4885PTGS2 26/4885MEN1 2067/4885 |
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | ALOX15, SOD1, ALOX12 | MT-CO2 3002/4885PTGS2 188/4885MEN1 4509/4885 |
| US-20260083751-A1 | ALLOSTERIC MODULATORS OF ANDROGEN RECEPTOR COACTIVATOR RECRUITMENT FOR CRPC THERAPY | AR, NCOA3, NR5A1 | MT-CO2 1443/4885PTGS2 1563/4885MEN1 4600/4885 |
| US-20250241922-A1 | ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JAK1, TNF, CYP4A11 | MT-CO2 1289/4885PTGS2 37/4885MEN1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.